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Abstract Nitric oxide (NO) is an important regulator of
renal transport processes. In the present study, we investi-
gated the role of NO, produced by inducible NO synthase
(iNOS), in the regulation of renal ATP-binding cassette
(ABC) transporters in vivo during endotoxemia. Wistar–
Hannover rats were injected with lipopolysaccharide
(LPS
+) alone or in combination with the iNOS inhibitor,
aminoguanidine. Controls received detoxified LPS (LPS
−).
After LPS
+, proximal tubular damage and a reduction in
renal function were observed. Furthermore, iNOS mRNA
and protein, and the amount of NO metabolites in plasma
and urine, increased compared to the LPS
− group. Coad-
ministration with aminoguanidine resulted in an attenuation
of iNOS induction and reduction of renal damage. Gene
expression of 20 ABC transporters was determined. After
LPS
+, a clear up-regulation in Abca1, Abcb1/P-glycopro-
tein (P-gp), Abcb11/bile salt export pump (Bsep), and
Abcc2/multidrug resistance protein (Mrp2) was found,
whereas Abcc8 was down-regulated. Up-regulation of
Abcc2/Mrp2 was accompanied by enhanced calcein excre-
tion. Aminoguanidine attenuated the effects on transporter
expression. Our data indicate that NO, produced locally by
renal iNOS, regulates the expression of ABC transporters in
vivo. Furthermore, we showed, for the first time, expression
and subcellular localization of Abcb11/Bsep in rat kidney.
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AKI acute kidney injury
BSA bovine serum albumin
Bsep bile salt export pump
BUN blood urea nitrogen
calcein-AM calcein-acetoxymethylester
ET endothelin
FENa fractional sodium excretion
FR fractional reabsorption
GFR glomerular filtration rate
HBSS Hank’s balanced salt solution
IL interleukin
LPS lipopolysaccharide
M-MLV Moloney murine leukemia virus
Mrp multidrug resistance protein
NF-κB nuclear factor kappa B
NOx NO metabolites
NOS nitric oxide synthase
P-gp P-glycoprotein
RPP renal perfusion pressure
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Introduction
The free radical nitric oxide (NO) has been shown to play
an important role in various physiological processes in the
kidney, including salt and fluid reabsorption, renal hemo-
dynamics, renin secretion, and tubuloglomerular feedback
[1]. Endogenous NO is enzymatically produced from
conversion of the amino acid L-arginine to L-citrulline, a
reaction that is catalyzed by the enzyme NO synthase
(NOS). This enzyme exists in three isoforms; the neuronal
(nNOS) and endothelial, both of which are Ca
2+- and
calmodulin-dependent constitutive isoforms, and an induc-
ible (iNOS) isoform [2]. Mediators associated with sepsis,
such as endotoxin and the proinflammatory cytokines,
interleukin-1β (IL-1β), IL-2, and tumor necrosis factor-α
(TNF-α), have been shown to induce iNOS, thereby
increasing production of NO. Sustained, high-output gen-
eration of NO by iNOS can cause cell death and tissue
damage through lipid peroxidation, DNA damage, and
proapoptotic effects [3]. This is the result of NO itself and
the oxidant peroxynitrite, which is generated after reaction
of NO with superoxide anions [4].
In contrast to many other organs, iNOS is constitutively
expressed in the kidney, in particular in the medulla and in
proximal tubules [5]. Many in vivo animal studies showed
the importance of iNOS as a contributor to the pathophys-
iology of acute kidney injury (AKI). For example, it has been
shown that selective chemical inhibitors of iNOS [6, 7], NO
scavengers [8], iNOS gene knockout mice [9], or antisense
oligodeoxynucleotides to iNOS [10] resulted in less renal
tubular injury and improved structural and functional
outcome. This renoprotective effect was partly due to the
rescue of tubular epithelial cells from injury by NO [3].
Using killifish renal proximal tubules, we found previ-
ously that NO hasa regulatory role inthetransport activity of
the ATP-binding cassette (ABC) transporter multidrug
resistance protein 2 (Abcc2/Mrp2) via an intracellular
signaling pathway in response to the action of several
nephrotoxic chemicals in vitro [11]. This pathway involved
at least endothelin (ET) release, binding to the basolateral
ETB receptor, and activation of NOS, soluble guanylyl
cyclase, and protein kinase C [12]. A similar regulatory
pathway was found for the ABC transporter P-glycoprotein
(Abcb1/P-gp) in rat brain capillaries [13]. Both studies in-
dicate that the activation of NOS is most likely Ca
2+-in-
dependent and we concluded that the production of NO is a
result of the activation of iNOS.
The proximal tubule is responsible for the excretory
transport of xenobiotics, xenobiotic metabolites, and waste
products of metabolism from blood into urine. Consequent-
ly, the proximal tubule is also an important target for toxic
effects and is often the first site of damage in AKI [14].
Luminal transport proteins, like the ABC transporters
ABCB1/P-gp, ABCC2/MRP2, and ABCC4/MRP4, are
important efflux transporters in the kidney [15]a n d ,
therefore, play a role in the detoxification of tubule cells.
The observed effects of NO on Abcc2/Mrp2 in killifish
proximal tubule may be part of the normal progression of
cellular events that occur during AKI.
In the present study, we hypothesized that iNOS has a
role in the regulation of renal ABC transporters during
nephrotoxicity in vivo. An endotoxemia model was used in
which rats were exposed to lipopolysaccharide (LPS), and
the gene expression of 20 ABC transporters was evaluated.
In addition, we examined the effect of the iNOS inhibitor,
aminoguanidine, to determine whether the change in
expression of the renal efflux transporters is caused directly
by NO generated by iNOS.
Materials and methods
Animals and experimental design
Specified pathogen-free male Wistar–Hannover rats (240–
295 g; purchased from Harlan, Zeist, The Netherlands)
were kept under routine laboratory conditions at the Central
Animal Laboratory of the Radboud University Nijmegen
Medical Centre. This strain was used because they do not
develop hydronephrosis spontaneously like normal Wistar
rats, which in turn could have a down-regulating effect on
iNOS expression [16]. The local Animal Care Committee
approved all experimental procedures.
Different pilot studies have been conducted to determine
the route of administration, intravenously or intraperito-
neally (IP), concentration of the endotoxin LPS (LPS
+,
Escherichia coli 0127:B8, Sigma-Aldrich, Zwijndrecht,
The Netherlands) and aminoguanidine (Sigma-Aldrich),
and the time point of coadministration in this strain. LPS
and aminoguanidine were dissolved in sterile Hank’s
balanced salt solution (HBSS, Gibco, Paisly, UK) supple-
mented with 10 mM 4-(2-hydroxyethyl)-1-piperazine
ethanesulfonic acid (HEPES, Gibco), and set to pH 7.4 with
NaOH.
Thirty rats were, stratified to body weight, injected IP
with 5 mg/kg LPS
+ and were killed after 3, 6, 12, 24, or
48 h (n=6 for each experimental group). Fifteen rats served
as controls and received 10 mg/kg detoxified LPS (LPS
−,
n=3 per group), in which the biologically active compo-
nent, lipid A, essential for the activation of NOS, is lacking
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appeared to be satisfactory to allow a reduction and refine-
ment of animals in this group. Twelve rats were injected IP
with both 5 mg/kg LPS
+ and, after 1 h, 100 mg/kg of the
iNOS inhibitor aminoguanidine (Sigma-Aldrich), and were
killed 6 and 12 h after LPS
+ (n=6 per group). For the
isolated perfused kidney experiments, six rats received
LPS
+, four received LPS
−, and four were untreated and
served as controls, and were killed after 12 h as described
under the “Isolated kidney perfusion” section.
To collect urine before and after the injection, rats were
housed in metabolic cages, washed with 2% chlorohexidine
(Genfarma, Zaandam, The Netherlands) to prevent bacterial
growth. Urine volumes were recorded and samples were
snap-frozen in liquid nitrogen and stored at −80°C until
assayed. During the experiment, body weight and body
temperature were determined. At indicated time points after
LPS injection, the rats were anesthetized with 5% isoflur-
ane and heparin (125 IU/100 g) was injected via the penile
vein to minimize blood clotting. The left kidney was
removed, divided in four pieces, and snap-frozen in liquid
nitrogen for immunohistology or fixed in Bouin’s solution
for routine histology. Arterial blood was obtained by aortic
puncture and the rats were killed by exsanguination. The
right renal vein was punctured and, subsequently, the
kidney was perfused with HBSS–HEPES for 2 min at
7.5 ml/min (Minipuls 2, Gilson, Villiers-le-Bel, France).
After perfusion, the kidney was removed, divided, and
snap-frozen in liquid nitrogen for quantitative real-time
polymerase chain reaction (RQ-PCR) and Western blotting.
Thrombocyte and leukocyte counts were determined in
blood as inflammatory parameters, and the concentrations
of creatinine, urea, protein, glucose, and sodium were
analyzed in blood and urine by routine clinical chemistry.
The activity of alkaline phosphatase, a proximal tubule
injury marker, was determined in 26-fold diluted urine
samples, as described before [18].
Determination of mRNA expression
RNA was isolated using a Mikro-dismembrator U
(Sartorius B. Braun Biotech, Melsungen, Germany). To
prevent RNA degradation, we washed the metal cylinders
with 0.5 M NaOH. Perfused kidneys were pulverized
(2,000 rpm, 30 s) and transferred in ice-cold TRIzol
reagent (Invitrogen, Breda, The Netherlands), and then
RNA was isolated as described previously [19]. RQ-PCR
on cDNA was performed according to the TaqMan®
protocol in optical tubes using either the ABI PRISM
7700 single reporter Sequence Detection System (n=6,
Applied Biosystems, Zwijndrecht, The Netherlands) or the
ABI/PRISM 7900HT Gene Expression Micro Fluidic Card
Sequence Detection System (three pooled samples from
nine different rats, Applied Biosystems) according to the
manufacturer’s instructions. All experiments were per-
formed in triplicate. Different rat genes were amplified
with a predeveloped Gene Expression Assay, provided by
Applied Biosystems.
Western blotting
Total membrane and cytosolic fractions from perfused
kidneys were isolated using a Mikro-dismembrator U
(Sartorius BBI Systems GmbH, Melsungen, Germany;
2,000 rpm for 30 s) and subjected to Western blotting as
described previously [20]. Protein concentration was
determined with the Bio-Rad protein assay (Bio-Rad,
Hercules, CA, USA) using bovine serum albumin (BSA)
as standard. Samples were separated on a 6 or 12% sodium
dodecylsulfate polyacrylamide gel and transferred to
Hybond-C pure nitrocellulose membrane (Amersham,
Buckinghamshire, UK). The membrane was incubated
overnight at 4°C with antibodies against NOSII/iNOS
(1:1,000, according to Vos et al. [21]), ABCB1/P-gp
(1:200, C219, DakoCytomation, Dako, Denmark), Abcc2/
Mrp2 (1:250, M2III-6, Alexis Biochemicals, San Diego,
CA, USA), ABCC4/MRP4 (1:1,000, as described by van
Aubel et al. [22]), Abcb11/bile salt export pump (Bsep)
(1:1,000, kindly provided by Dr. Bruno Stieger, University
Hospital Zürich, Switzerland), or β-actin (1:10,000, Sigma)
in Tris-buffered saline supplemented with 0.1% Tween-20
and 1% nonfat dried milk.
Nitrate and nitrite determination
The total amount of the stable NO metabolites (NOx),
nitrate and nitrite, were determined as a measure of NO
radicals production, using the Griess reaction, according to
Moshage et al. [23]. Heparinized plasma was diluted 1:4
and urine samples were diluted 1:40 or 1:80 with distilled
water. Each sample was determined in triplicate. Calibra-
tion curves were made with sodium nitrite and sodium
nitrate in distilled water. The nitrate recovery was 90–100%
over the entire range tested (0–50 μmol/l). The coefficient
of variation between the different experiments was less
than 5%.
Histology and immunohistology
Kidneys fixed in Bouin’s solution were dehydrated, em-
bedded in paraplast (Amsterstad, Amsterdam, The Nether-
lands), and cut into 3-μm sections, which were stained with
periodic acid-Schiff for routine histology. For immunohis-
tologic studies, serial tissue sections of 1.5 μm were cut
from frozen kidneys using a cryostat as described previ-
ously [24]. The slices were incubated for 60 min at room
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(1:200, according to Vos et al. [21]) or ABCB1/P-gp (1:50,
C219, DakoCytomation) in PBS supplemented with 1%
BSA. For the antibodies peroxynitrite (1:500, Sigma) and
Abcb11/Bsep (1:1,000, as described by Huls et al. [24]),
cryostat slices of 4 μm were used, fixed in acetone for
5 min. Endogenous peroxidase was blocked by incubation
with 5% H2O2 for 5 min, and nonspecific protein binding
was blocked with 10% normal goat serum (Vector,
Burlingame, CA, USA) in PBS for 10 min at room
temperature. Slices were incubated with the primary
antibody in PBS 1% BSA overnight at 4°C. Primary
antibody was detected using the Vectastain Elite peroxidase
ABC kit (Vector) with 3,3′-diaminobenzidine as substrate.
Finally, slices were counterstained with hematoxylin,
dehydrated, and mounted in mounting medium. Sections
were examined with a confocal laser-scanning microscope
(Leica lasertechnik GmbH, Heidelberg, Germany).
Isolated kidney perfusion
Twelve hours after the administration of LPS
+ (n=6) or
LPS
− (n=4), the transport activity of Abcc2/Mrp2 was
determined by monitoring the urinary excretion of calcein
in an isolated perfused rat kidney, as described in detail
previously [25]. Briefly, rats were anesthetized IP with
pentobarbital (6 mg/100 g), and furosemide was injected IP
(1 mg/100 g) to prevent deterioration of the distal nephron.
Fig. 1 iNOS mRNA and protein. a iNOS mRNA expression in rat
kidney at different time points after LPS
+ was determined with RQ-
PCR without (closed bars, n=6) or with coadministration of amino-
guanidine (gray bars, n=6). The iNOS mRNA expression was
normalized for the GAPDH CT value (16.06±0.04, n=15), and ΔCT
values for the LPS
− were set to 1. Data are expressed as mean±SE.
Significantly different compared to the LPS
− (double asterisks P<
0.01, triple asterisks P<0.001, quadruple asterisks P<0.0001).
Cytosolic fractions of rat kidney were isolated and expression of
iNOS was determined by Western blotting. Representative images (n=
4) show maximal iNOS protein expression 6 h after LPS
+ adminis-
tration (b), and coadministration with aminoguanidine reversed this
induction (c)
Fig. 2 NOx in plasma and urine. NOx levels in plasma and urine
were measured at various times after LPS
− (open bars, n=3) or LPS
+
(closed bars, n=6) treatment or LPS
+ together with aminoguanidine
(gray bars, n=6). a Blood samples show a peak concentration at 12 h
and coadministration with aminoguanidine reversed this increase at
both 6 and 12 h. b The urinary excretion of NOx increased 12 h after
LPS
+ treatment, and aminoguanidine returned this increase to baseline
levels. Data are expressed as mean±SE. Significantly different
compared to the LPS
− (single asterisks P<0.05, double asterisks P<
0.01, triple asterisks P<0.001) or LPS
+ (double sharp signs P<0.01,
triple sharp signs P<0.001)
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kidney was excised and placed in a fluid bath with a
constant temperature of 37.5°C and rats were killed by
exsanguination. Vitamin B12 was used for the determina-
tion of the glomerular filtration rate (GFR) and calcein-
acetoxymethylester was used as a source for the fluorescent
substrate calcein [25].
Statistical analysis
Values are given as mean ± SE. Differences between the
experimental groups were tested using one-way ANOVA
with Bonferroni’s correction or two-way ANOVA corrected
for repeated measurements. A two-sided P value<0.05 was
considered significant.
Fig. 3 Immunofluorescence microscopic analysis of iNOS and
peroxynitrite in the kidney. a–c Representative immunohistochemical
images show that iNOS (green staining) is expressed in the vicinity of
the apical membrane (P-gp counterstaining, red) in all segments of the
proximal tubule 12 h after LPS
+ treatment. d, e Formation of 3-
nitrotyrosine-protein adducts, a reliable biomarker of peroxynitrite
generation, were visible in the cortex in peritubulary capillaries and
proximal tubules 12 h after LPS
+ treatment. f, g Coadministration with
aminoguanidine resulted in attenuated formation of 3-nitrotyrosine-
protein adducts at 12 h. G glomerulus, asterisks peritubular staining,
P proximal tubule, D distal tubule. Original magnification d, f ×200
and a–c, e, g ×400
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Signs of inflammation
A few hours after LPS
+ administration, inflammatory
symptoms appeared, like diarrhea and piloerection. Body
temperature was elevated after 24 h and the loss in body
weight increased from −3% (t=3 h), due to normal
circadian rhythm, to 12% (t=48 h), compared to the
controls (Table a in the supplementary material 1). Further-
more, administration of LPS
+ resulted in the expected
leucopenia (t=3 h) followed by leukocytosis (t=48 h) and
thrombocytopenia, with a maximum at 48 h. Coadminis-
tration of LPS
+ with aminoguanidine did not affect the
inflammatory parameters, except for a greater loss in body
weight 12 h after LPS administration.
iNOS induction after LPS treatment
RQ-PCR was used to determine the iNOS mRNA levels in
kidney samples. The relative expression of iNOS in LPS
−
rats was normalized for the average cycle threshold (CT)
value for the housekeeping gene, GAPDH (CT=16.06±
0.04, n=15), and set to 1. GAPDH expression remained
stable during endotoxemia (CT=16.22±0.09, n=42). Fur-
thermore, no circadian rhythm for the different genes was
detected in control animals.
Analysis of three separate experiments revealed a more
than 40,000 times induction in iNOS mRNA 3 h after LPS
+
compared to controls (Fig. 1a), which decreased with time,
but was still 100 times higher than control values 48 h after
LPS
+. Treatment with both LPS
+ and aminoguanidine slight-
ly, but not significantly, reversed iNOS mRNA induction
Table 1 Renal functional parameters
Kidney function Time (h) Controls (LPS
−) LPS
+ LPS
+ and aminoguanidine
Total urine volume (ml) 3 1.6±0.24 1.7±0.27
6 2.4±0.65 4.45±0.98 7.3±0.76
12 3.2±0.57 10.0±0.70
a 9.4±0.65
a
24 11.5±0.25 13.7±2.11
48 23.5±3.47 18.0±1.57
BUN (mmol/l) 3 6.6±0.20 9.9±0.74
6 4.6±0.72 14.0±1.48
b 12.1±0.82
b
12 6.3±0.24 12.3±1.38
a 15.4±1.27
b
24 7.0±0.58 10.6±0.58
48 6.5±0.10 9.1±0.38
Blood creatinine (mmol/l) 3 0.035±0.002 0.049±0.002
b
6 0.039±0.002 0.053±0.002
b 0.043±0.019
d
12 0.037±0.002 0.048±0.002
c 0.036±0.032
e
24 0.038±0.001 0.051±0.001
a
48 0.042±0.001 0.052±0.001
Glucose excretion (μmol/h) 3 0.290±0.045 0.481±0.341
6 0.333±0.086 0.420±0.100 0.478±0.051
12 0.425±0.106 0.537±0.054 0.332±0.080
24 0.254±0.006 0.984±0.039
c
48 0.325±0.037 0.606±0.128
Creatinine clearance (ml/min) 3 1.33±0.12 0.78±0.19
6 1.06±0.15 0.87±0.09 0.93±0.35
12 1.01±0.05 0.90±0.03 1.01±0.13
24 1.19±0.02 0.91±0.20
48 1.00±0.07 1.08±0.37
FENa (%) 3 0.816±0.004 0.365±0.073
6 1.046±0.145 0.358±0.094
b 1.423±0.310
e
12 1.094±0.097 0.458±0.075
a 1.610±0.282
e
24 1.070±0.024 0.429±0.065
c
48 1.033±0.077 0.121±0.024
a
Data are expressed as mean±SE, n=6 for each time point for both LPS
+ and LPS
+ +aminoguanidine and n=3 for LPS
−
FENa fractional sodium excretion
aSignificantly different compared to the control group; P<0.01
bSignificantly different compared to the control group; P<0.001
cSignificantly different compared to the control group; P<0.05
dSignificantly different compared to the LPS
+ group; P<0.01
eSignificantly different compared to the LPS
+ group; P<0.001
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+ alone (Fig. 1a). Maximal iNOS protein
expression was observed in cytosolic fractions 6 h after LPS
+,
and returned to LPS
− level at 48 h (Fig. 1b). In contrast to
its effect on iNOS mRNA expression, aminoguanidine
reversed the induction in protein expression (Fig. 1c).
NOx levels in plasma and urine were measured using the
Griess assay. An increase in NOx concentration in plasma
was already visible 3 h after LPS
+, with a peak concentra-
tion at 12 h. Coadministration with aminoguanidine
reversed the increase in NOx significantly at both 6 and
12 h (Fig. 2a). The urinary excretion of NOx increased 12 h
after LPS
+, and was still elevated 48 h later. Amino-
guanidine returned this increase to baseline levels at both
time points (Fig. 2b).
Renal localization of iNOS and formation of 3-nitro-
tyrosine-protein adducts, a reliable biomarker of peroxyni-
trite generation [26], were determined by immunohistology.
There was no iNOS staining visible in kidney sections of
rats treated with LPS
−. Positive iNOS staining was seen in
both experimental groups after LPS
+, in inflammatory cells,
and in proximal tubule cells. Forty-eight hours after LPS
+,
iNOS staining was no longer detectable. Figure 3 shows
representative immunohistochemical images with iNOS
expression in all segments of the proximal tubule (3A+C).
After colocalization with Abcb1/P-gp (3B), iNOS expres-
sion in the vicinity of the apical membrane was visible
(3A+C). 3-Nitrotyrosine-protein adducts were predomi-
nantly present in the cortex in peritubulary capillaries and
proximal tubules after LPS
+ (Fig. 3d,e). Coadministration
with aminoguanidine attenuated the formation of adducts in
the cortex (Fig. 3f,g).
Aminoguanidine restores the slightly impaired kidney
function and loss of brush border membrane
Kidney function was slightly impaired after LPS
+ as
indicated by increased blood urea nitrogen (BUN), an
increase in plasma creatinine, and an increased urinary
glucose excretion (Table 1). Furthermore, the urine/plasma
creatinine ratio was decreased (data not shown) as was the
creatinine clearance, although not significantly.
Histological examination after LPS
+ revealed damage to
the proximal tubules, compared to LPS
− (Fig. 4a,b). Loss
of brush border membranes and formation of vacuoles
Fig. 4 Proximal tubular damage during endotoxemia. Histological
examination after LPS
+ revealed damage to the proximal tubules
compared to LPS
−. a LPS
−-treated rat with intact brush border
membrane in proximal tubules. b Twelve hours after LPS
+, damage
to the proximal tubules is observed with loss of brush border
membranes and formation of vacuoles. c Treatment with both LPS
+
and aminoguanidine resulted in less damage to the proximal tubule.
Kidneys of LPS
+-treated rats killed after 24 or 48 h also showed signs
of proximal tubule damage (data not shown). Proximal tubules are
indicated by arrows. Original magnifications (a–c) ×400. d Histolog-
ical data are supported by an increase in the activity of alkaline
phosphatase, marker for proximal tubule damage, in urine samples
12 h after LPS
+ administration (closed bars, n=6), compared to
controls (open bars, n=3). Coadministration with aminoguanidine
(gray bars, n=6) reduced this proximal tubule damage. Data are
expressed as mean±SE. Significantly different compared to the LPS
−
(double asterisks P<0.01) or LPS
+ (sharp sign P<0.05)
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+-induced
damage to the proximal tubule (Fig. 4c). The activity of
alkaline phosphatase in urine samples was assayed to get
an indication of proximal tubule injury. Twelve hours after
LPS
+, the activity of alkaline phosphatase was increased in
urine samples and was still significantly increased after
48 h (Fig. 4d). Furthermore, the expression of kidney
injury molecule 1 (Kim-1 [27]) was strongly up-regulat-
ed, 400 times more than control values, 6 and 12 h after
LPS
+ (Table b in the supplementary material 1). Except for
BUN, aminoguanidine improved all parameters of renal
function, as shown in Table 1 and Fig. 4. No differences
in urinary protein excretion were found and, remarkably,
the fractional excretion of filtered sodium was decreased
(Table 1).
Furthermore, the mRNA expression of different bio-
transformation enzymes [28], enzymes involved in the NO
pathway [2] or known to be activated during oxidative
stress [29, 30] was determined. Twelve and 24 h after LPS
+
treatment, expression of the metabolizing enzymes gluta-
Table 2 Gene expression of efflux transporters during endotoxemia
Gene symbol Protein synonym Assay IDs Delta CT values
a
LPS
−
(controls)
LPS
+
t=3 h
LPS
+
t=6 h
LPS
+
t=12 h
LPS
+
t=24 h
LPS
+
t=48 h
LPS
+ +
amino
t=6 h
LPS
+ +
amino
t=12 h
Abca1 Abca 1 Rn00710172_m1 7.1±0.31 5.1±
0.16
5.8±
0.22
7.3±
0.55
7.3±
0.35
6.8±
0.23
6.1±
0.23
8.0±
0.12
Abca2 Abca 2 Rn00577821_m1 3.5±0.40 3.5±
0.35
4.1±
0.15
4.5±
0.38
4.3±
0.35
3.6±
0.06
4.4±
0.38
4.4±
0.12
Abca5 Abca 5 Rn00597824_m1 9.8±0.06 9.8±
0.35
9.8±
0.10
9.5±
0.12
10.0±
0.23
10.2±
0.21
9.5±
0.25
9.7±
0.35
Abcb1a P_gp Rn00591394_m1 8.4±0.01 Fig. 5a
Abcb1b P_gp Rn00561753_m1 10.8±
0.04
Fig. 5b
Abcb4 Abcb 4 Rn00562185_m1 10.7±
0.62
12.3±
0.16
12.5±
0.21
12.8±
0.15
10.9±
0.15
7.3±
0.42
13.2±
0.46
12.4±
0.24
Abcb6 Abcb 6 Rn00589801_m1 5.5±0.35 5.9±
0.26
6.4±
0.25
6.5±
0.52
5.9±
0.38
5.4±
0.14
6.4±
0.25
6.2±
0.32
Abcb9 Abcb 9 Rn00573757_m1 8.1±0.20 8.5±
0.38
9.3±
0.29
8.8±
0.17
8.6±
0.10
8.7±
0.17
9.2±
0.42
8.9±
0.15
Abcb11 Bsep Rn00582179_m1 10.5±
0.40
8.6±
0.37
10.3±
0.24
11.9±
0.21
8.7±
0.17
5.4±
0.49
9.9±
0.21
9.7±
0.21
Abcc1 Mrp1 Rn00574093_m1 5.9±0.25 6.2±
0.26
6.1±
0.25
6.1±
0.25
6.3±
0.21
5.9±
0.23
6.4±
0.40
6.2±
0.15
Abcc2 Mrp2 Rn00563231_m1 6.7±0.31 Fig. 5c
Abcc3 Mrp3 Rn00589786_m1 8.4±0.15 8.7±
0.12
8.8±
0.508
8.6±
0.06
8.0±
0.35
8.2±
0.12
8.8±
0.32
8.7±
0.23
Abcc4 Mrp4 Rn01465699_q1 6.6±0.06 Fig. 5d
Abcc5 Mrp5 Rn00588341_m1 7.1±0.01 7.9±
0.03
7.6±
0.15
6.4±
0.06
6.5±
0.50
6.5±
0.38
7.6±
0.45
6.4±
0.36
Abcc6 Mrp6 Rn00578778_m1 7.0±0.14 7.0±
0.01
8.4±
0.21
8.4±
0.12
7.8±
0.05
6.8±
0.35
8.6±
0.07
8.3±
0.14
Abcc8 Sur1 Rn00564778_m1 11.5±
0.40
11.4±
0.21
11.4±
0.26
13.4±
0.15
14.8±
0.15
13.2±
0.25
11.7±
0.23
13.7±
0.31
Abcc9 Sur2 Rn00564842_m1 6.8±0.01 7.7±
0.26
8.4±
0.31
8.1±
0.15
7.2±
0.32
6.8±
0.40
8.0±
0.35
8.2±
0.32
Abcg1 Abcg1 Rn00585262_m1 6.8±0.15 7.8±
0.25
6.8±
0.25
7.1±
0.40
6.8±
0.31
6.7±
0.21
6.4±
0.31
7.3±
0.36
Abcg2 Abcg2 Rn00710585_m1 4.1±0.24 4.5±
0.07
4.6±
0.21
5.0±
0.06
4.5±
0.14
4.5±
0.07
4.9±
0.42
5.2±
0.07
Abcg5 Abcg5 Rn00587092_m1 18.8±
0.29
b
aData of nine pooled samples, measured in triplicate, are expressed as mean ± SD
bLow expressed transport protein: CT value is not considered as valid
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diphosphate-glucuronosyltransferases (UDPGT1a6) was
down-regulated (Table b in the supplementary material 1,
at least a 2 times lower expression). The arginine metabolic
enzymes, argininosuccinate synthetase and arginase 2, were
not changed after LPS
+. In contrast, arginase 1 mRNA
expression was reduced. The gene expression of the ETB
receptor, which gets activated as part of the NO-dependent
signaling pathway regulating Abcb1/P-gp and Abcc2/Mrp2
[13, 31], did not change during endotoxemia. Three and 6 h
after LPS
+ the mRNA expressions of super oxide dismutase
2, heam-oxygenase 1, and nuclear factor κB (NF-κB) were
up-regulated (i.e., at least a 2 times higher expression).
Coadministration of aminoguanidine had no effect on the
gene expression of all these proteins. In contrast, amino-
guanidine reversed the down-regulation of nNOS gene
expression during endotoxemia (Table b in the supplemen-
tary material 1).
LPS
+ treatment affects ABC drug transporter expression
in the kidney
The mRNA expression of 20 renal ABC transporters was
profiled. Abcb1a/P-gp, Abcb1b/P-gp, Abcc2/Mrp2 and
Abcc4/Mrp4 expression was determined with the ABI
PRISM 7700 single reporter sequence detection system. In
rodents, Abcb1/P-gp exists as two functional isoforms,
which are encoded by two different genes: Abcb1a and
Abcb1b [32]. The other ABC transporters were assessed
with the ABI/PRISM 7900HT Gene Expression Micro
Fluidic Card (Table 2). Their expression was normalized for
the average CT value for GAPDH, as described for iNOS.
Other housekeeping genes, like glucuronidase and hypo-
xanthine guanine phosphoribosyl transferase 1, gave com-
parable values to GAPDH (data not shown). Abcb1b/Pg-p
and Abcc2/Mrp2 were clearly up-regulated 3 h after LPS
+
and were still elevated 12 and 24 h later (Fig. 5b,c).
Furthermore, Abcb1a/P-gp and Abcc4/Mrp4 were slightly,
but not significantly, increased 12 h after LPS
+ treatment
(Fig. 5a,d). Table 2 presents a list of the expression of other
transporter genes during endotoxemia. Abca1 showed a
slight up-regulation 3 h after LPS
+, but returned to basal
levels within 12 h. Furthermore, Abcb11 was up-regulated,
but only significantly after 48 h. A down-regulation was
observed for Abcb4 and Abcc8 (at least a 2 times lower
expression). The expression of the Abcg genes was not
affected by endotoxemia.
Coadministration with aminoguanidine blocked the
induction in mRNA expression of both Abcb1b/P-gp and
Abcc2/Mrp2 at 6 and 12 h, respectively (Fig. 5b,c).
Furthermore, aminoguanidine reduced the increased protein
expression of both transporters 12 h after LPS
+ treatment
(Fig. 6b,d), indicating a regulatory role for NO in the
expression of these efflux transporters. Abcc4/Mrp4 protein
Fig. 5 mRNA expression of
different renal ABC transport-
ers. Gene expression of Abcb1a/
P-gp (a) and Abcb1b/P-gp (b),
Abcc2/Mrp2 (c), and Abcc4/
Mrp4 (d) were determined in rat
kidney at different time points
after LPS
− (open bars, n=3) or
LPS
+ (closed bars, n=6) treat-
ment or LPS
+ together with
aminoguanidine (gray bars, n=
6). ΔCT values for the LPS
−,
given in Table 2, were set to 1.
Data are expressed as mean±SE.
Significantly different compared
to the LPS
− (single asterisks P<
0.05, double asterisks P<0.01,
triple asterisks P<0.001) or
LPS
+ (sharp signs P<0.05)
Pflugers Arch - Eur J Physiol (2007) 454:321–334 329levels, on the other hand, decreased even more after
treatment with both LPS
+ and aminoguanidine. Gene
expression levels of other transporters were not affected
by aminoguanidine (Table 2).
The expression patterns of Abcb1/P-gp, Abcb11, Abcc2/
Mrp2, and Abcc4/Mrp4 were investigated further. Using
total membrane fractions, we found an up-regulation of
Abcb1/P-gp 6 h after LPS
+, with maximal protein expression
12 and 24 h after LPS
+ (Fig. 6a). Abcb11 is the major liver
canalicular bile salt export pump (Bsep), but surprisingly,
this transporter is also expressed at the apical membrane of
mice renal proximal tubule, as we discovered recently [24].
In agreement with an increased mRNA expression, Abcb11/
Bsep protein was up-regulated after LPS
+ (Fig. 6c).
Although we are not completely certain whether the C219
antibody against Abcb1/P-gp also detects Abcb11/Bsep [33],
our Western blot results showed expression of Abcb1/P-gp,
with a molecular weight of 130 kDa, and it does not seem to
cross-react with Bsep at 160 kDa.
By using immunohistochemistry, the expression and
localization of Abcb11/Bsep was investigated in endotoxe-
mic rat kidneys. In agreement with mouse kidney, positive
staining was observed in the apical membranes of the
proximal tubule 12 h after LPS
+ treatment (Fig. 7). In
addition, we observed staining in rat glomerular endothe-
lium and peritubular capillaries.
Furthermore, a clear increase in Abcc2/Mrp2 protein was
observed after LPS
+ (Fig. 6d), but a down-regulation in
Fig. 7 Distribution of Abcb11/
Bsep in rat kidney cortex. a, b
Representative immunohisto-
chemical images show apical
staining in proximal tubules (in-
dicated by arrows). In addition,
glomerular and peritubular
staining of Bsep in the cortex
was found. G glomerulus,
asterisks peritubular staining, P
proximal tubule, D distal tubule.
Original magnification in a
×200, and in b ×400
Fig. 6 Protein expression of different renal ABC transporters. Total
membrane fractions of rat kidney were isolated and expression of
Abcb1/P-gp (a, b), Abcb11/Bsep (c), Abcc2/Mrp2 (d, e), and Abcc4/
Mrp4 (f, g) was determined by Western blotting. Representative
images (n=4) show maximal Abcb1/P-gp protein expression 12 and
24 h after LPS
+ (a), and coadministration with aminoguanidine
reversed this induction (b). The protein expression of Abcb11/Bsep
was up-regulated 12 h after LPS
+ treatment, which was reversed by
aminoguanidine (c). Maximal Abcc2/Mrp2 protein expression was
seen 12 h after LPS
+ (d) and aminoguanidine reversed this induction
(e). Abcc4/Mrp4 protein expression was down-regulated during
endotoxemia (f), which was intensified by aminoguanidine (g)
330 Pflugers Arch - Eur J Physiol (2007) 454:321–334Abcc4/Mrp4 was found (Fig. 6f). We measured the function
of Abcc2/Mrp2 by monitoring the urinary excretion of
calcein in an isolated perfused rat kidney 12 h after LPS
+ or
LPS
−. A 16±3% increase in calcein excretion was observed
after LPS
+, as shown in Fig. 8. We do not expect calcein to
be a Bsep substrate because Mrp2-deficient (TR−) rats
clearly showed that calcein excretion was highly reduced
[25], despite the presence of Bsep in these strains
(unpublished data). Twenty-four hours after LPS
+, Abcc2/
Mrp2 activity was still elevated, although not significantly.
In accordance, endotoxemia affected renal function as
observed by diminished GFR and fractional reabsorption
of water in isolated perfused rat kidneys (Table 3).
Discussion
In the present study, we investigated the role of NO,
produced by iNOS, in the differential expression of renal
ABC transporters in rats in vivo. A clear up-regulation
of Abca1, Abcb1/P-gp, Abcb11/Bsep, and Abcc2/Mrp2
expression was found after LPS
+. In addition, we observed
a functional up-regulation of Abcc2/Mrp2 in perfused
kidneys. This supports a detoxifying role of the efflux
pump, which is in accordance with the up-regulation of
Abcc2/Mrp2 protein in killifish renal tubules [34, 35], in rat
kidney, and in MDCKII cells overexpressing human
ABCC2/MRP2 after long-term exposure to the nephrotox-
icant gentamicin [20], and of abcb1/P-gp in mouse kidneys
after ischemic reperfusion injury [24]. Indeed, blocking
Abcb1/P-gp during endotoxemia leads to further renal
damage (Heemskerk, Wouterse, Russel, and Masereeuw,
preliminary findings). The renal drug transporters are likely
to be under direct influence of NO produced by iNOS, as
coadministration of the iNOS inhibitor, aminoguanidine,
attenuated the LPS-induced effects on transporter expres-
sion. Aminoguanidine treatment results in decreased NO
production and, subsequently, reduced oxidative stress by
decelerating the formation of peroxynitrite. Under these
conditions, less toxic metabolites may be produced,
explaining the restoration in transporter expression and
reversal of proximal tubular damage.
In contrast to our findings, Cherrington et al. [36]
reported that coadministration of aminoguanidine failed to
change the expression of different hepatic drug transporters
during endotoxemia. This discrepancy might be due to
organ differences and the fact that Cherrington et al.
pretreated the animals with the NOS inhibitor, whereas we
gave aminoguanidine 1 h after LPS
+. The lack of an effect
of aminoguanidine on the expression of different biotrans-
formation enzymes, enzymes involved in the iNOS path-
way and during oxidative stress, supports a direct function
of NO itself in ABC transporter regulation.
Table 3 Functional parameters of isolated perfused rat kidneys in control rats (no additional treatment) and after exposure to LPS
− or LPS
+ for
12 h
Parameter Controls (n=4) LPS
− (n=4) LPS
+ (n=6)
GFR (μl/min) 350±25 380±17 290±20
a
Diuresis (μl/min) 18.6±1.8 21.1±1.3 17.4±1.0
FRwater (%) 94.7±0.2 94.5±0.3 92.7±0.6
a
RPP (mmHg)
b 88.4±1.5 84.5±1.7 88.7±1.0
Data are expressed as mean ± SE of four to six perfused kidney experiments over the period 25-115 min. Untreated rats served as controls for this
model. Kidneys were perfused for 150 min as described in the “Materials and methods” section
aSignificantly different from perfused control kidney (P<0.05)
bConstant flow during the experiments was 18±0.5 ml/min
FR fractional reabsorption, RPP renal perfusion pressure
Fig. 8 Renal calcein excretion in isolated perfused rat kidneys. Secretion
of the fluorescent calcein into the urine was measured after 12 h in
untreated (closed squares control; n=4), LPS
− (open squaresn=4), or
LPS
+ (trianglesn=6) rats. Urinary excretion was corrected for GFR.
Significantly different compared to the LPS
− (asterisk P<0.05)
Pflugers Arch - Eur J Physiol (2007) 454:321–334 331The role of two up-regulated efflux pumps, Abca1 and
Abcb11/Bsep, in the kidney is unknown. In humans,
ABCA1 is widely expressed and found to be the causative
gene in Tangier disease, a disorder of cholesterol transport
between tissues and the liver, mediated by binding of the
cholesterol onto high-density lipoprotein particles [37].
ABCA1 controls the extrusion of membrane phospholipid
and cholesterol toward specific extracellular acceptors;
however, the exact role of the protein in this process is
not known. Moreover, its expression and function in the
kidney requires further investigation. The presence of
Abcb11/Bsep, the major canalicular bile salt export pump,
was recently demonstrated by us in mouse kidney [24], and
here we show a clear apical expression in rat kidney
proximal tubules for the first time as well. Hence, the
function of Abcb11/Bsep in the kidney still needs to be
determined. In addition to their up-regulation in the kidney,
we found a down-regulation of Abcb1/P-gp, Abcc2/Mrp2,
and Abcb11/Bsep in the liver (data not shown). This is in
agreement with previous findings for the hepatic expression
of the transporters during inflammation [36, 38–40], ob-
structive jaundice [41], and cholestasis [42]. An induction
of the transporters in the kidney during liver failure may
function as a compensatory elimination mechanism to
reduce enhanced levels of circulating bile salts caused by
endotoxin-induced cholestasis [39] and/or to protect prox-
imal tubular cells against the higher exposure via primary
urine.
A differential regulation was found for Abcc4. Although
this transporter is expressed in the same nephron segments as
Abcb1/P-gp and Abcc2/Mrp2, the apically expressed efflux
pump clearly has a distinct regulation. In killifish, we
previously found renal proximal tubules exposed to neph-
rotoxicants or ET-1 that Abcc2/Mrp2-mediated transport and
Mrp2 expression in the luminal membrane were increased
after 24 h [34], whereas the expression of Abcc4/Mrp4
remained unchanged [35]. Furthermore, Abcc4/Mrp4 protein
levels in rat kidney were decreased during cholestasis in
contrast to the Abcc2/Mrp2 levels [43]. No changes in
Abcc4/Mrp4 mRNA were found, suggesting a posttranscrip-
tional regulation of transporter expression, including phos-
phorylation and protein routing. A down-regulation of ABC
transporters, as observed for Abcc8/Sur1 and initially also
for Abcb4, may be explained by the different functions of
these ABC members in the kidney.
LPS itself may affect transporter expression after binding
to the Toll-like receptor 4 and a second, not yet identified,
factor through activation of NOS-dependent pathways, as
was found for Abcb1/P-gp in rat brain capillaries [44].
Furthermore, systemic TNF-α, released during endotoxe-
mia, may regulate efflux pumps, including ABC trans-
porters [45, 46]. This cytokine might act through NOS
activation [44], but also through a pathway that does not
involve iNOS-derived NO during endotoxin-associated
renal failure [47]. Furthermore, regulation of iNOS after
exposure to LPS occurs at the level of gene transcription
and may require activation of the NF-κB pathway [48]. It
has been shown previously that an up-regulation of Abcb1/
P-gp in renal failure, i.e., after ischemic–reperfusion
damage [24] or exposure to cadmium [49], might be
signaled through an NF-κB-dependent pathway. Consistent
with these findings, we observed a clear induction
(sevenfold) of NF-κB expression 3 h after LPS
+ as well.
Selective inhibition of renal iNOS has important impli-
cations for the treatment of septic acute kidney disease.
Changes in the expression levels of renal drug transporters
alters the pharmacokinetics of many clinically important
drugs [50] and has implications for the prediction of overall
drug disposition during sepsis. For example, glucocorti-
coids are substrates for Abcb1/Pg-p and are often pre-
scribed for their anti-inflammatory properties in septic
patients. An up-regulation of Abcb1/Pg-p, as observed in
our study, might have consequences for therapeutic levels
of these substrates [51].
In conclusion, after LPS
+, a clear up-regulation in
Abca1, Abcb1/P-gp, Abcb11/Bsep, and Abcc2/Mrp2 was
found, whereas Abcc8/Sur1 was down-regulated. Abcb4
and Abcc4/Mrp4 show a differential pattern during the
course of endotoxemia. The renal drug transporters are
likely to be under direct influence of NO produced by
iNOS, as coadministration of the iNOS inhibitor, amino-
guanidine, attenuated the LPS-induced effects on their
expression. Apparently, an up-regulation of important
efflux pumps diminishes the renal accumulation of toxic
compounds and attenuates further proximal tubular damage
during endotoxemia.
Acknowledgements We thank Jeroen J.M.W. van den Heuvel for
his help with the RQ-PCR experiments. Furthermore, we thank Dr.
Han Moshage (University Hospital Groningen, The Netherlands) for
providing us with the antibody against iNOS and Dr. Bruno Stieger
(University Hospital Zürich, Switzerland) for the antibody against
Bsep. S. Heemskerk was supported by a grant from The Netherlands
Organisation for Scientific Research (NWO).
References
1. Ortiz PA, Garvin JL (2002) Role of nitric oxide in the regulation
of nephron transport. Am J Physiol Renal Physiol 282:F777–F784
2. Xie Q, Nathan C (1994) The high-output nitric oxide pathway:
role and regulation. J Leukoc Biol 56:576–582
3. Goligorsky MS, Brodsky SV, Noiri E (2004) NO bioavailability,
endothelial dysfunction, and acute renal failure: new insights into
pathophysiology. Semin Nephrol 24:316–323
4. Noiri E, Nakao A, Uchida K, Tsukahara H, Ohno M, Fujita T,
Brodsky S, Goligorsky MS (2001) Oxidative and nitrosative stress in
acute renal ischemia. Am J Physiol Renal Physiol 281:F948–F957
332 Pflugers Arch - Eur J Physiol (2007) 454:321–3345. Ortiz PA, Garvin JL (2003) Cardiovascular and renal control in
NOS-deficient mouse models. Am J Physiol Regul Integr Comp
Physiol 284:R628–R638
6. Schwartz D, Mendonca M, Schwartz I, Xia Y, Satriano J, Wilson
CB, Blantz RC (1997) Inhibition of constitutive nitric oxide
synthase (NOS) by nitric oxide generated by inducible NOS after
lipopolysaccharide administration provokes renal dysfunction in
rats. J Clin Invest 100:439–448
7. Szabo C, Southan GJ, Thiemermann C (1994) Beneficial effects
and improved survival in rodent models of septic shock with S-
methylisothiourea sulfate, a potent and selective inhibitor of
inducible nitric oxide synthase. Proc Natl Acad Sci USA
91:12472–12476
8. Yoshida M, Akaike T, Wada Y, Sato K, Ikeda K, Ueda S, Maeda
H (1994) Therapeutic effects of imidazolineoxyl N-oxide against
endotoxin shock through its direct nitric oxide-scavenging
activity. Biochem Biophys Res Commun 202:923–930
9. Ling H, Edelstein C, Gengaro P, Meng X, Lucia S, Knotek M,
Wangsiripaisan A, Shi Y, Schrier R (1999) Attenuation of renal
ischemia–reperfusion injury in inducible nitric oxide synthase
knockout mice. Am J Physiol 277:F383–F390
10. Noiri E, Peresleni T, Miller F, Goligorsky MS (1996) In vivo
targeting of inducible NO synthase with oligodeoxynucleotides
protects rat kidney against ischemia. J Clin Invest 97:2377–2383
11. Notenboom S, Miller DS, Smits P, Russel FG, Masereeuw R (2002)
Role of NO in endothelin-regulated drug transport in the renal
proximal tubule. Am J Physiol Renal Physiol 282:F458–F464
12. Notenboom S, Miller DS, Smits P, Russel FG, Masereeuw R
(2004) Involvement of guanylyl cyclase and cGMP in the
regulation of Mrp2-mediated transport in the proximal tubule.
Am J Physiol Renal Physiol 287:F33–F38
13. Hartz AM, Bauer B, Fricker G, Miller DS (2004) Rapid regulation
of P-glycoprotein at the blood–brain barrier by endothelin-1. Mol
Pharmacol 66:387–394
14. van de Water FM, Masereeuw R, Russel FG (2005) Function and
regulation of multidrug resistance proteins (MRPs) in the renal
elimination of organic anions. Drug Metab Rev 37:443–471
15. Russel FG, Masereeuw R, van Aubel RA (2002) Molecular aspects
of renal anionic drug transport. Annu Rev Physiol 64:563–594
16. Zhou Y, Takahashi G, Yonamine K (2003) Down-regulation of
inducible nitric oxide synthase (iNOS) in rat with congenital
hydronephrosis. Int J Urol 10:536–543
17. Traylor LA, Mayeux PR (1997) Nitric oxide generation mediates
lipid A-induced oxidant injury in renal proximal tubules. Arch
Biochem Biophys 338:129–135
18. Mircheff AK, Wright EM (1976) Analytical isolation of plasma
membranes of intestinal epithelial cells: identification of Na, K-
ATPase rich membranes and the distribution of enzyme activities.
J Membr Biol 28:309–333
19. Heemskerk S, Pickkers P, Bouw MP, Draisma A, van der Hoeven
JG, Peters WH, Smits P, Russel FG, Masereeuw R (2006) Up-
regulation of renal iNOS during human endotoxemia and sepsis is
associated with proximal tubule injury. Clin J Am Soc Nephrol
1:853–862
20. Notenboom S, Wouterse AC, Peters B, Kuik LH, Heemskerk S,
Russel FG, Masereeuw R (2006) Increased apical insertion of the
multidrug resistance protein 2 (MRP2/ABCC2) in renal proximal
tubules following gentamicin exposure. J Pharmacol Exp Ther
318:1194–1202
21. Vos TA, Gouw AS, Klok PA, Havinga R, van Goor H, Huitema S,
Roelofsen H, Kuipers F, Jansen PL, Moshage H (1997)
Differential effects of nitric oxide synthase inhibitors on endotox-
in-induced liver damage in rats. Gastroenterology 113:1323–1333
22. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG
(2002) The MRP4/ABCC4 gene encodes a novel apical organic
anion transporter in human kidney proximal tubules: putative
efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol
13:595–603
23. Moshage H, Kok B, Huizenga JR, Jansen PL (1995) Nitrite and
nitrate determinations in plasma: a critical evaluation. Clin Chem
41:892–896
24. Huls M, van den Heuvel JJ, Dijkman HB, Russel FG, Masereeuw
R (2006) ABC transporter expression profiling after ischemic
reperfusion injury in mouse kidney. Kidney Int 69:2186–2193
25. Masereeuw R, Notenboom S, Smeets PH, Wouterse AC, Russel
FG (2003) Impaired renal secretion of substrates for the multidrug
resistance protein 2 in mutant transport-deficient (TR−) rats. J Am
Soc Nephrol 14:2741–2749
26. Beckman JS, Koppenol WH (1996) Nitric oxide, superoxide, and
peroxynitrite: the good, the bad, and ugly. Am J Physiol 271:
C1424–C1437
27. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV
(2006) Urinary kidney injury molecule-1: a sensitive quantitative
biomarker for early detection of kidney tubular injury. Am J
Physiol Renal Physiol 290:F517–F529
28. Shelby MK, Cherrington NJ, Vansell NR, Klaassen CD (2003)
Tissue mRNA expression of the rat UDP-glucuronosyltransferase
gene family. Drug Metab Dispos 31:326–333
29. Wang W, Jittikanont S, Falk SA, Li P, Feng L, Gengaro PE, Poole
BD, Bowler RP, Day BJ, Crapo JD, Schrier RW (2003) Interaction
among nitric oxide, reactive oxygen species, and antioxidants
during endotoxemia-related acute renal failure. Am J Physiol
Renal Physiol 284:F532–F537
30. Sikorski EM, Hock T, Hill-Kapturczak N, Agarwal A (2004) The
story so far: molecular regulation of the heme oxygenase-1 gene
in renal injury. Am J Physiol Renal Physiol 286:F425–F441
31. Masereeuw R, Terlouw SA, van Aubel RA, Russel FG, Miller
DS (2000) Endothelin B receptor-mediated regulation of ATP-
driven drug secretion in renal proximal tubule. Mol Pharmacol
57:59–67
32. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P,
Housman DE (1989) The three mouse multidrug resistance (mdr)
genes are expressed in a tissue-specific manner in normal mouse
tissues. Mol Cell Biol 9:1346–1350
33. Vos TA, Ros JE, Havinga R, Moshage H, Kuipers F, Jansen PL,
Muller M (1999) Regulation of hepatic transport systems involved
in bile secretion during liver regeneration in rats. Hepatology
29:1833–1839
34. Terlouw SA, Graeff C, Smeets PH, Fricker G, Russel FG,
Masereeuw R, Miller DS (2002) Short- and long-term influences
of heavy metals on anionic drug efflux from renal proximal
tubule. J Pharmacol Exp Ther 301:578–585
35. Notenboom S, Miller DS, Kuik LH, Smits P, Russel FG,
Masereeuw R (2005) Short-term exposure of renal proximal
tubules to gentamicin increases long-term multidrug resistance
protein 2 (Abcc2) transport function and reduces nephrotoxicant
sensitivity. J Pharmacol Exp Ther 315:912–920
36. Cherrington NJ, Slitt AL, Li N, Klaassen CD (2004) Lipopoly-
saccharide-mediated regulation of hepatic transporter mRNA
levels in rats. Drug Metab Dispos 32:734–741
37. Brunham LR, Singaraja RR, Hayden MR (2006) Variations on a
gene:rareand commonvariantsinABCA1andtheir impactonHDL
cholesterol levels and atherosclerosis. Annu Rev Nutr 26:105–129
38. Vos TA, Hooiveld GJ, Koning H, Childs S, Meijer DK,
Moshage H, Jansen PL, Muller M (1998) Up-regulation of
the multidrug resistance genes, Mrp1 and Mdr1b, and down-
regulation of the organic anion transporter, Mrp2, and the
bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology
28:1637–1644
39. Hartmann G, Vassileva V, Piquette-Miller M (2005) Impact of
endotoxin-induced changes in P-glycoprotein expression on dispo-
sition of doxorubicin in mice. Drug Metab Dispos 33:820–828
Pflugers Arch - Eur J Physiol (2007) 454:321–334 33340. Teng S, Piquette-Miller M (2005) The involvement of the
pregnane X receptor in hepatic gene regulation during inflamma-
tion in mice. J Pharmacol Exp Ther 312:841–848
41. Tanaka Y, Kobayashi Y, Gabazza EC, Higuchi K, Kamisako T,
Kuroda M, Takeuchi K, Iwasa M, Kaito M, Adachi Y (2002)
Increased renal expression of bilirubin glucuronide transporters in
a rat model of obstructive jaundice. Am J Physiol Gastrointest
Liver Physiol 282:G656–G662
42. Lee J, Azzaroli F, Wang L, Soroka CJ, Gigliozzi A, Setchell KD,
Kramer W, Boyer JL (2001) Adaptive regulation of bile salt
transporters in kidney and liver in obstructive cholestasis in the
rat. Gastroenterology 121:1473–1484
43. Denk GU, Soroka CJ, Takeyama Y, Chen WS, Schuetz JD, Boyer
JL (2004) Multidrug resistance-associated protein 4 is up-
regulated in liver but down-regulated in kidney in obstructive
cholestasis in the rat. J Hepatol 40:585–591
44. Hartz AM, Bauer B, Fricker G, Miller DS (2006) Rapid
modulation of P-glycoprotein-mediated transport at the blood–
brain barrier by tumor necrosis factor-alpha and lipopolysac-
charide. Mol Pharmacol 69:462–470
45. Jiang Q, Matsuzaki Y, Li K, Uitto J (2006) Transcriptional
regulation and characterization of the promoter region of the
human ABCC6 gene. J Invest Dermatol 126:325–335
46. Lee G, Piquette-Miller M (2003) Cytokines alter the expression
and activity of the multidrug resistance transporters in human
hepatoma cell lines; analysis using RT-PCR and cDNA micro-
arrays. J Pharm Sci 92:2152–2163
47. Knotek M, Rogachev B, Wang W, Ecder T, Melnikov V, Gengaro
PE, Esson M, Edelstein CL, Dinarello CA, Schrier RW (2001)
Endotoxemic renal failure in mice: role of tumor necrosis factor
independent of inducible nitric oxide synthase. Kidney Int
59:2243–2249
48. Xie QW, Kashiwabara Y, Nathan C (1994) Role of transcription
factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol
Chem 269:4705–4708
49. Thevenod F, Friedmann JM, Katsen AD, Hauser IA (2000)
Up-regulation of multidrug resistance P-glycoprotein via nuclear
factor-kappaB activation protects kidney proximal tubule cells
from cadmium- and reactive oxygen species-induced apoptosis.
J Biol Chem 275:1887–1896
50. Sun H, Frassetto L, Benet LZ (2006) Effects of renal failure on
drug transport and metabolism. Pharmacol Ther 109:1–11
51. Huang ZH, Murakami T, Okochi A, Yumoyo R, Nagai J, Takano
M (2001) Expression and function of P-glycoprotein in rats with
carbon tetrachloride-induced acute hepatic failure. J Pharm
Pharmacol 53:873–881
334 Pflugers Arch - Eur J Physiol (2007) 454:321–334